利伐沙班对心力衰竭合并心房颤动患者凝血因子及预后情况的效果观察

来源期刊：广州医药 | 151-156 发布时间：2024-03-06 收稿时间：2025/11/13 18:50:56 阅读量：26

作者：: 姚慧慧,

蒋建青,

关键词：: 心力衰竭心房颤动起搏器植入术凝血因子心肌损伤预后情况; heart failure atrial fibrillation cardiac resynchronization therapy with defibrillator coagulation factors myocardial injury prognostic situation

DOI：: 10.3969/j.issn.1000-8535.2024.02.009

收稿时间：: 2023-08-08
修订日期：
接收日期：
引用总数：: 2

目的观察利伐沙班对心力衰竭（HF）合并心房颤动（AF）患者凝血因子及预后情况的影响。方法采用前瞻性研究,纳入平顶山市第二人民医院2021年1月—2022年4月期间收治的123例HF合并AF患者,以数字随机表法将入组患者分为常规组（61例）和试验组（62）例,两组均行起搏器植入术（CRTD）治疗,常规组予以常规抗凝治疗辅助CRTD,试验组予以利伐沙班辅助CRTD,所有患者术后均开展一年随访,比较两组患者治疗前后的抗Xa凝血因子、心肌损伤标志物、心功能指标变化情况,以及术后血栓栓塞、心血管死亡事件发生情况。结果治疗前,两组患者的Xa凝血因子,心肌损伤标志物,心功能指标比较差异无统计学意义（P>0.05）;在不同抗凝方案下,观察组治疗1 d后的抗Xa凝血因子为（130.44±20.18）IU/mg,治疗3 d后的抗Xa凝血因子为（115.36±20.77）IU/mg,治疗7 d的抗Xa凝血因子为（90.25±20.44）IU/mg,均低于常规组[（145.33±20.19）IU/mg、（128.45±20.16）IU/mg、（103.34±20.17）IU/mg],差异有统计学意义（P<0.05）。治疗后,试验组的肌酸激酶同工酶为（7.52±2.16）U/L,心肌肌钙蛋白Ⅰ为（0.52±0.12）ng/mL,乳酸脱氢酶为（126.41±20.45）U/L,均低于常规组[（8.44±2.28）U/L、（0.94±0.31）ng/mL、（140.33±20.25）U/L],差异有统计学意义（P<0.05）。治疗后,观察组的左室射血分数为（56.12±10.41）%,高于常规组（50.24±10.33）%,左室舒张末期内径为（47.11±10.25）mm,左室舒张末期容积为（36.72±10.43）mL,均低于常规组（53.28±10.14）mm、（42.77±10.36）mL,差异有统计学意义（P<0.05）。随访期间,试验组的血栓栓塞事件发生率为4.84%（3/62）,心血管死亡事件发生率为3.23%（2/62）,均低于常规组[19.67%（12/61）、14.75%（9/61）],差异有统计学意义（P<0.05）。结论利伐沙班辅助CRTD能有效增强HF合并AF患者的抗Xa凝血因子活性,对减轻心肌损伤、改善心功能并降低血栓栓塞或心血管死亡风险均有积极意义。

Objective To observe the effect of rivaroxaban on coagulation factors and prognosis in patients of heart failure（HF）with atrial fibrillation（AF）．Methods This is a prospective study．The patients were included from January 2021 to April 2022 in Pingdingshan Second People’s Hospital．The study subjects were 123 patients with HF and AF．The enrolled patients were divided into the conventional group（61 cases）and the experimental group（62 cases）by the method of digital random table．Both groups were treated with cardiac resynchronization therapy with defibrillator（CRTD）．The conventional group was treated with conventional anticoagulation therapy to assist CRTD,and the experimental group was treated with rivaroxaban to assist CRTD．All patients were followed up for one year after surgery,the changes in anti-Xa coagulation factors,myocardial injury markers,cardiac function indicators,as well as the incidence of postoperative thromboembolism and cardiovascular death events between the two groups of patients before and after treatment were compared．Results Before treatment,there were no statistically significant differences in Xa coagulation factor,myocardial injury markers and cardiac function indicators between the two groups of patients（P>0.05）．Under different anticoagulation regimens,the anti-Xa coagulation factor levels in the observation group were（130.44±20.18）IU/mg after 1 day of treatment,（115.36±20.77）IU/mg after 3 days of treatment,and（90.25±20.44）IU/mg after 7 days of treatment,which were lower than that in the conventional group [（145.33±20.19）IU/mg,（128.45±20.16）IU/mg,（103.34±20.17）IU/mg]（P<0.05）．After treatment,the CK-MB level of the experimental group was（7.52±2.16）U/L,cTnI was（0.52±0.12）ng/mL,and LDH was（126.41±20.45）U/L,which were lower than that of the conventional group [（8.44±2.28）U/L,（0.94±0.31）ng/mL,（140.33±20.25）U/L]（P<0.05）．After treatment,the left ventricular ejection fraction of the observation group was（56.12±10.41）%,which was higher than the conventional group（50.24±10.33）%,left ventricular diameter was（47.11±10.25）mm,left ventricular end disastolic volume was（36.72±10.43）mL,which were lower than the conventional group（53.28±10.14）mm,（42.77±10.36）mL（P<0.05）．During the follow-up period,the incidence of thromboembolism events in the experimental group was 4.84%（3/62）,and the incidence of cardiovascular death events was 3.23%（2/62）,which was lower than the conventional group [19.67%（12/61）,14.75%（9/61）]（P<0.05）．Conclusions Rivaroxaban assisted CRTD can effectively enhance the activity of anti-Xa coagulation factors in patients with HF and AF,which has positive significance in reducing myocardial injury,improving cardiac function and reducing the risk of thromboembolism or cardiovascular death．

1、陈静文,裴菱花,陈超,等.80岁以上非瓣膜性心房颤动患者抗凝方案的调查研究[J].中国全科医学,2020,23(35):4477-4482.

2、宋晓丹. 利伐沙班与华法林治疗老年心力衰竭合并心房颤动患者的疗效对比研究[J].中国现代药物应用,2019,13(21):115-116.

3、魏长民,刘福珍,崔玉强.利伐沙班联合Gsα基因沉默对心力衰竭大鼠心肌损伤的保护作用[J].中国老年学杂志,2022,42(8):1984-1987.

4、邸平,李绵洋.抗Ⅹa活性检测在抗凝治疗中的临床应用现状与前景[J].协和医学杂志,2021,12(4):456-459.

5、 COHEN O,LEVY M S,AGENO W.Rivaroxaban for the treatment of venous thromboembolism in pediatric patients[J].Expert Rev Cardiovasc Ther,2020,18(11):733-741.

6、陈桂尼,刘运仲,王月婵,等.心脏瓣膜病患者术后应用肝素钠与华法林抗凝致出血情况的比较及华法林抗凝致出血风险模型的构建[J].中国医药,2023,18(3):345-349.

7、 MANGRUM J S,SASUNDERS J A,CHAIYAKUNPRUK N,et al.A scoping review of direct oral anticoagulant ambulatory management practices[J].J Thromb Thrombolysis,2023,55(4):700-709.

8、刘慧慧,李小明,马英.利伐沙班与达比加群酯对心力衰竭合并心房颤动起搏器植入术后囊袋出血及血栓栓塞事件影响研究[J].创伤与急危重病医学,2023,11(2):130-131.

9、华伟,顾敏,宿燕岗,等.中国慢性心力衰竭患者中左心室多位点起搏有效性和安全性的观察和评价[J].中华心律失常学杂志,2022,26(2):152-158.

10、张建军. 永久性起搏器植入围手术期需要考虑的细节及技术要点[J].临床心血管病杂志,2021,37(11):975-978.

11、宋学莲,王帆,张飞飞,等.心脏起搏器植入术后并发症的相关临床分析[J].中国循证心血管医学杂志,2021,13(8):966-968.

12、吴雪迎,姚可欣,龙德勇,等.心房颤动管理指南的变迁与发展[J].中国医刊,2021,56(2):120-123.

13、郭艺芳. 2022年美国心力衰竭管理指南更新要点解读[J].中国全科医学,2022,25(17):2051-2054.

14、 MILWIDSKY A,GREIDINGER D,FREDMAN S,et al.Echocardiographic killip classification[J].J Am Soc Echocardiogr,2022,35(3):287-294.

15、孙沙沙,洛佳坤,徐伟豪,等.高龄老年非瓣膜性心房颤动患者使用利伐沙班抗凝治疗单中心经验[J].中国循证心血管医学杂志,2021,13(3):298-301.

16、刘家玥,黄英杰,霍晨星,等.不同抗凝用药方案对房颤合并心衰患者疗效与安全性的网状Meta分析[J].中国医院药学杂志,2021,41(5):502-511.

17、李乐,郑黎晖.心脏起搏器置入术的相关并发症及围术期管理[J].中国临床医生杂志,2022,50(9):1017-1019.

18、 UNBERDORBEN M,von HEYMANN C,SANTAMARI A,et al.Thromboembolic and bleeding risks in edoxaban patients with pacemaker and cardiac monitoring procedures:Outcomes of the Global EMIT program[J].Pacing Clin Electrophysiol,2022,45(1):83-91.

19、胡华超,陈娴雅,谢思媛,等.心房颤动合并心力衰竭患者的临床特点及治疗现状分析的多中心研究[J].中国全科医学,2023,26(5):541-549.

20、张健瑜,梁茜,许兆延,等.高龄老年慢性心力衰竭患者在临床表现及危险因素方面的特点探讨[J].中国现代药物应用,2020,14(14):24-26.

1、黎霏霏,宋丹丹,潘春荣.老年慢性心力衰竭患者血清SCD-1和sVEGFR-2表达水平及其与预后的评估价值研究[J].广州医药,2025,56(02):241-246.DOI:10.20223/j.cnki.1000-8535.2025.02.015.

2、纪雅娟,马雨佳.比索洛尔与利伐沙班联合应用在冠心病心力衰竭患者中的临床疗效观察[J].中国现代药物应用,2025,19(23):84-87.DOI:10.14164/j.cnki.cn11-5581/r.2025.23.022.